What is NVS's current stock price?

As of now, NVS is trading at $131.34, with a daily change of -0.34%.

What are the risks associated with NVS stock?

NVS Key risk is its Low Risk Level, .

What is NVS next earnings date?

NVS next earnings report is scheduled for Oct 28, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NVS Stock Analysis & IQ Rating | Novartis AG

NVS

Novartis AG

$131.34

-$0.45 | -0.34%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 133.55

MKT CAP

$ 276.39B

52W Low

$ 96.06

VOL

$ 535.55K

P/E Ratio

19.14

AVG VOL

$ 1.46M

RSI

60.35

TREND

Uptrend

NVS Stock IQ

Login to see Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NVS Target Price

Login to display

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Outperform the market

NVS Rewards

Expands stock buyback program

Risk Analysis

NVS Risk Analysis

Downgraded on weak valued

Chart

$122.23 (+7.45%)

$116.66 (+12.58%)

$116.7 (+12.54%)

$109.38 (+20.08%)

1year

6month

3month

1month

NVS Risk Level

NVS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

NVS Analysts Opinion

NVS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is negative and it remained unchanged from the past 3 months

NVS Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

96%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

90%

NVS Street Opinion

NVS Street view is extremely bullish and have positive views on the near-term outlook

NVS Performance Sentiment

Sentiments overview associated with NVS events and the stock performance.

96%

4%

Positive

Negative

23 out of 24
events present

1 out of 24
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$131.43

Resistance
Price

$122.23

Current Price Range

$132.39

Show methods +

NVS Earnings

The TTM reflects 12-month period, providing review of NVS financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

55,186

51,722

46,660

+8.75%

Cost of Revenue

13,107

12,827

12,472

+2.51%

Gross Profit

42,079

38,895

34,188

+10.94%

Operating Exp

25,395

24,351

24,419

+1.98%

Operating Inc

16,684

14,544

9,769

+30.68%

Net Interest Inc

-883

-686

-419

-

Interest Exp

1,098

1,006

855

+13.32%

Interest Inc

-

568

627

-

Other Inc Exp

-193

-218

-227

-

EPS Growth

6.92

5.92

7.15

-1.62%

NVS Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.9

Next Earnings Date: Oct 28, 2025

Linked to NVS

IQ

Close Price

Change

PFE

4.11

24.85

+0.65%

AZN

4.15

83.22

-0.78%

MRK

4.07

87.62

+1.54%

SNY

3.93

49.66

-0.14%

LLY

4.18

799.57

-1.16%

NVS Latest Analysis +

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial. On Friday NVS) shared results from the five-year analysis of the Phase 3 NATALEE .The data demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali (median follow-up: 58.4 months).Results showed a 28.4% reduction in risk of recurrence in patients with high-risk stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early ...

Fri Oct 17, 2025

$131.43 | +0.50%

Potential

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML. ® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph CML-CP) in all lines of treatment.12. In the trial Scemblix demonstrated superior major molecular response (MMR) rates when compared against all TKIs (imatinib nilotinib dasatinib and bosutinib) and also when compared against imatinib alone12. Patients treated w

Fri Oct 17, 2025

$131.43 | +0.50%

Activity

Potential

Novartis reports positive data from late-stage trial for Fabhalta.

Thu Oct 16, 2025

$130.77 | +0.58%

Activity

Novartis Strengthens Kidney Disease Pipeline With Promising Data. NVS) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta (iptacopan) in adults .NVS is in positive territory. IgA nephropathy also known as Berger'.s disease is an autoimmune kidney disease in which clumps of antibodies specifically immunoglobulin A (IgA) accumulate in the kidney'.s filters leading to inflammation and damage.Fabhalta statistically significant clinically meaningful sup

Thu Oct 16, 2025

$130.77 | +0.58%

Activity

NVS Reports Positive Late-Stage Data on Kidney Disease Drug . Novartis Fabhalta shows strong phase III results in slowing IgA nephropathy progression paving the way for full FDA approval in 2026.

Thu Oct 16, 2025

$130.77 | +0.58%

Activity

Earnings

Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria. Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30 Novartis announced the US FDA approval of its drug Rhapsido (remibrutinib). This oral pill is approved for use in adult patients with chronic spontaneous urticaria/CSU whose symptoms persist despite treatment with H1 antihistamines. Rhapsido is a pill taken twice daily [….]

Mon Oct 13, 2025

$129.12 | -0.70%

Activity

Potential

Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX.

Fri Oct 10, 2025

$130.03 | -0.81%

Activity

The Zacks Analyst Blog Highlights SAP Novartis Philip Morris International ImmuCell and ClearOne. SAPs cloud and AI push Novartis strong drug lineup and Philip Morris smoke-free growth headline Zacks latest analyst picks.

Thu Oct 9, 2025

$131.06 | -0.97%

Potential

Top Stock Reports for SAP Novartis & Philip Morris. SAP Novartis and Philip Morris headline todays top Zacks reports each showing strong momentum and strategic growth drivers despite industry headwinds.

Wed Oct 8, 2025

$132.31 | +0.58%

Potential

Heres Why Novartis (NVS) is a Strong Value Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Wed Oct 8, 2025

$132.31 | +0.58%

Potential

FAQ About NVS Stock Insights

What is NVS current stock price?

What are NVS stock strengths?

What risks are associated with NVS stock?

When is NVS next earnings report?

What is NVS market cap and volume?

What is NVS's current Stock IQ?

Should I buy NVS stock right now?

Is NVS a Strong Buy right now?

What does a 'Strong Buy' rating mean for NVS?

What does a 'Strong Sell' rating mean for NVS?

What factors influence NVS's Stock IQ?

Explore our NVS Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NVS Stock Strategies
Effective Risk Management

FIND US ON

Receive our NVS Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NVS

Novartis AG

Current Price

$131.34

-$0.45 | -0.34%

52W High

$ 133.55

MKT CAP

$ 276.39B

52W Low

$ 96.06

VOL

$ 535.55K

P/E Ratio

19.14

AVG VOL

$ 1.46M

RSI

60.35

TREND

Uptrend

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Outperform the market

NVS Rewards

Expands stock buyback program

Risk Analysis

NVS Risk Analysis

Downgraded on weak valued

Linked to NVS

Symbol

IQ

Close

Change

PFE

4.11

24.85

+0.65%

AZN

4.15

83.22

-0.78%

MRK

4.07

87.62

+1.54%

SNY

3.93

49.66

-0.14%

LLY

4.18

799.57

-1.16%

NVS Stock IQ

Login to unlock Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$122.23 (+7.45%)

$116.66 (+12.58%)

$116.7 (+12.54%)

$109.38 (+20.08%)

1year

6month

3month

1month

NVS Analysts Opinion

NVS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is negative and it remained unchanged from the past 3 months

NVS Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

96%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

90%

NVS Street Opinion

NVS Street view is extremely bullish and have positive views on the near-term outlook

NVS Risk Level

NVS has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

NVS Performance Sentiment

Sentiments overview associated with NVS events and the stock performance.

96%

4%

Positive

Negative

23 out of 24
events present

1 out of 24
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$131.43

Resistance
Price

$122.23

Current Price Range

$132.39

Show methods +

NVS Earnings

The TTM data reflects the most recent 12-month period, providing overview of NVS financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

55,186

51,722

46,660

+8.75%

Cost of Revenue

13,107

12,827

12,472

+2.51%

Gross Profit

42,079

38,895

34,188

+10.94%

Operating Exp

25,395

24,351

24,419

+1.98%

Operating Inc

16,684

14,544

9,769

+30.68%

Net Interest Inc

-883

-686

-419

-

Interest Exp

1,098

1,006

855

+13.32%

Interest Inc

-

568

627

-

Other Inc Exp

-193

-218

-227

-

EPS Growth

6.92

5.92

7.15

-1.62%

NVS Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.9

Next Earnings Date: Oct 28, 2025

NVS Latest Analysis

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial. On Friday NVS) shared results from the five-year analysis of the Phase 3 NATALEE .The data demonstrated a sustained benefit at a median of two years after a three-year treatment with Kisqali (median follow-up: 58.4 months).Results showed a 28.4% reduction in risk of recurrence in patients with high-risk stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early ...

Fri Oct 17, 2025

$131.43 | +0.50%

Potential

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML. ® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph CML-CP) in all lines of treatment.12. In the trial Scemblix demonstrated superior major molecular response (MMR) rates when compared against all TKIs (imatinib nilotinib dasatinib and bosutinib) and also when compared against imatinib alone12. Patients treated w

Fri Oct 17, 2025

$131.43 | +0.50%

Activity

Potential

Novartis reports positive data from late-stage trial for Fabhalta.

Thu Oct 16, 2025

$130.77 | +0.58%

Activity

Novartis Strengthens Kidney Disease Pipeline With Promising Data. NVS) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta (iptacopan) in adults .NVS is in positive territory. IgA nephropathy also known as Berger'.s disease is an autoimmune kidney disease in which clumps of antibodies specifically immunoglobulin A (IgA) accumulate in the kidney'.s filters leading to inflammation and damage.Fabhalta statistically significant clinically meaningful sup

Thu Oct 16, 2025

$130.77 | +0.58%

Activity

NVS Reports Positive Late-Stage Data on Kidney Disease Drug . Novartis Fabhalta shows strong phase III results in slowing IgA nephropathy progression paving the way for full FDA approval in 2026.

Thu Oct 16, 2025

$130.77 | +0.58%

Activity

Earnings

Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria. Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30 Novartis announced the US FDA approval of its drug Rhapsido (remibrutinib). This oral pill is approved for use in adult patients with chronic spontaneous urticaria/CSU whose symptoms persist despite treatment with H1 antihistamines. Rhapsido is a pill taken twice daily [….]

Mon Oct 13, 2025

$129.12 | -0.70%

Activity

Potential

Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX.

Fri Oct 10, 2025

$130.03 | -0.81%

Activity

The Zacks Analyst Blog Highlights SAP Novartis Philip Morris International ImmuCell and ClearOne. SAPs cloud and AI push Novartis strong drug lineup and Philip Morris smoke-free growth headline Zacks latest analyst picks.

Thu Oct 9, 2025

$131.06 | -0.97%

Potential

Top Stock Reports for SAP Novartis & Philip Morris. SAP Novartis and Philip Morris headline todays top Zacks reports each showing strong momentum and strategic growth drivers despite industry headwinds.

Wed Oct 8, 2025

$132.31 | +0.58%

Potential

Heres Why Novartis (NVS) is a Strong Value Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Wed Oct 8, 2025

$132.31 | +0.58%

Potential

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVS. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NVS Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVS Stock trends

NVS Stock performance

NVS Stock analysis

NVS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NVS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NVS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

NVS Stock Analysis & IQ Rating | Novartis AG

NVS Stock IQ

NVS Target Price

NVS Risk Level

NVS Analysts Opinion

NVS Street Consensus

NVS Performance Sentiment

Technical Price Levels

NVS Financial Health

Explore our NVS Stock insights

Receive our NVS Daily Alerts

NVS Stock IQ

NVS Street Consensus

NVS Risk Level

Technical Price Levels

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVS. We're here to help you make informed investment decisions today.

Receive our NVS Daily Alerts

NVS Runner Alarm